NEWS

Joana Correia, Founder and CEO of Exogenus Therapeutics, will be a featured speaker at Exosomes Europe, taking place in London on June 5th and 6th.    Joana will present a talk titled "Extracellular vesicles in human health: opportunities and challenges," where she...

Exogenus Therapeutics is proud to announce a strategic investment led by 3xP Global. This funding of 3xP Global will significantly advance the development of Exogenus lead product, Exo-101, that derived from umbilical cord blood cells and has shown promise in multiple...

Exogenus Therapeutics CEO, Joana Simões Correia, participated in a roundtable organized by Cell & Gene Therapy Insights and Miltenyi, as part of a discussion panel about “Diagnostic & therapeutic uses for extracellular vesicles (EVs): insights into a rapidly...

A meeting report from the 2021 massivEVs workshop entitled “Large-scale production of extracellular vesicles: Report on the “massivEVs” ISEV workshop” is now online. The massivEVs workshop took place on October 2021 and addressed the efforts towards large scale EV...

Exogenus Therapeutics announces that its exclusively licensed patent entitled “USE OF UMBILICAL CORD BLOOD DERIVED EXOSOMES FOR TISSUE REPAIR” has been granted in China and Korea. The patent describes the use of extracellular vesicles secreted by umbilical cord blood...

Exogenus Therapeutics was one of the 18 startups selected to take part in the Blue Bio Value Accelerator organized by Oceano Azul Foundation, Calouste Gulbekian Foundation and Maze. The accelerator aims to train and promote international startups working in the blue...

Exogenus Therapeutics CEO, Joana Simões Correia, is again an invited speaker at the 4th Exosome Based Therapeutic Development Summit, taking place in Boston, October 4th-6th. Joana’s talk will focus on the importance of EV quality control and on the therapeutic...

Labiotech, a Berlin-based digital media company covering biotech, recently published an article highlighting Portuguese success stories, which include Exogenus Therapeutics and other “neighbors” headquartered in Biocant (Cantanhede), such as Immunethep and...

Joana Correia, Exogenus’s co-founder, CEO and CSO is an invited speaker at the IX BiotechHealth Annual Symposium, organized by i3S and taking place on June 28th 2022. Joana will be taking us on a trip from her days as an academic researcher to founding and...

Today the final event of the InnoCore Challenge took place in Granada, Spain. Teams of MSc and PhD students were challenged to propose solutions for real problems faced by companies. Instead of focusing only on the scientific solutions, the teams also had to estimate...

https://www.exogenus-t.com/wp-content/uploads/2022/02/Press-Release-Boehringer-Exogenus-Therapeutics-300×150.png

Exogenus Therapeutics is one of the five companies presenting projects in the Innocore Challenge. The initiative is part of the project “InnoCore – Core Technologies for Education and Innovation in Life Sciences”, funded by the Erasmus+ programme, and combines...

Exogenus Therapeutics CEO, Joana Simões Correia, is again an invited speaker at the 3rd Exosome Based Therapeutic Development Summit, taking place virtually on November 17th and 18th, as part of a panel discussion about "Comparing Engineered & Naturally Derived...

Our team member Carla Pereira will be attending the massivEVs workshop, organized by ISEV, with a poster titled “Manufacturing and characterization of extracellular vesicles from umbilical cord mononuclearcells for future clinical use”. She will be sharing published...

Exogenus Therapeutics was announced as 1st Place in the category of BioTech on the 14th October 2021, at the International Trade Council's Annual Go Global Awards Ceremony. Founded in 2015, Exogenus Therapeutics is an early-stage R&D biotech company, dedicated to...

Exogenus Therapeutics announces that its exclusively licensed patent entitled “USE OF UMBILICAL CORD BLOOD DERIVED EXOSOMES FOR TISSUE REPAIR” has been granted in Japan. The patent describes the use of exosomes naturally secreted by umbilical cord blood mononuclear...

A recent study published in the Journal of Molecular Sciences illustrates how Exo-101 modulates cells and their microenvironment, to reduce inflammation and promote homeostasis. These results support the development of Exo-101 as an adjuvant therapy for inflammatory...

Exogenus published a study offering an in-depth look at the safety profile of umbilical cord blood-derived exosomes. Exo-101, a solution enriched in small extracellular vesicles produced by umbilical cord blood mononuclear cells (UCB-MNC-sEV), has consistently shown...

Patricia Freire, one of Exogenus’ scientists, presents some of our recent advances at the ISEV Annual Meeting, happening on May 18th to 21st, virtually. The talk, entitled “Umbilical cord blood-derived small extracellular vesicles: immune-modulating properties and...

Exogenus was the only Portuguese company selected to pitch at the European Innovation Council’s Investor Day on Health on May 18th and 19th to present its pioneering technology to leading Life Sciences investors from across the globe, featuring its Series A investment...

Labiotech.eu just published an article featuring the interview with Exogenus’ CEO and CSO, Joana Correia, discussing the disparity in funding opportunities seen in Europe vs USA. The article, which also quotes Antonin de Fougerolles (Evox Therapeutics, CEO) and...

Exosome RNA, an online publication featuring the hottest trends in global exosome research, recently highlighted Exogenus Therapeutics’ contribution to the field, by mentioning our recent publication in Stem Cells Translational Medicine. Exogenus Therapeutics...

Labiotech.eu, a biotechnology-centered online issue, published an article about exosomes, featuring Exogenus Therapeutics as one of the leading exosome biotechnology companies in Europe. The piece delves into the most recent advances in exosome-based therapeutics and...

A paper entitled “Development of an optimized and scalable method for isolation of umbilical cord blood‐derived small extracellular vesicles for future clinical use” was just published in STEM CELLS Translational Medicine. The publication details the protocol...

Joana Correia, CEO and CSO of Exogenus Therapeutics is an invited speaker at the 2nd Exosome Based Therapeutic Development Summit, taking place during November 11-12 (online). Joana will be joined by other world leaders in exosome development to discuss the pains and...

Joana Correia, founder, Executive Director and Chief Scientific Officer of Exogenus Therapeutics will be presenting at the 14th World Advanced Therapies and Regenerative Medicine Congress taking place 15th to 17th of May in London. Joana will be presenting Exogenus’s...

Exogenus Therapeutics is the winner of the 2nd edition of Prémio Empreendedor XXI, Portugal - North and Central Regions. This prize is organized by BPI and DayOne, a division of CaixaBank specialized in technological companies, in partnership with Agência Nacional de...

Exogenus is amongst the 500 deeptech startups running for the Hello Tomorrow Global Challenge. The Hello Tomorrow Global Challenge is a worldwide renowned science & technology startup competition designed specifically to address the needs of...

We are glad to announce that Graça Raposo, one of the first scientists worldwide who recognized the biological role of Extracellular Vesicles (EVs) in human biology, has joined our Advisory Board. Commonly referred within experts as “the mother of exosomes”, Graça...

Exogenus is developing promising therapeutics for the treatment of chronic and acute wounds, among which are diabetic foot ulcers, some of the most debilitating and hard-to-heal. The lead technology licensed and under development by Exogenus for the treatment of...

Exogenus was recognized at BioEurope 2017, one of the biggest biotech industry events! Listen to Joana Simões Correia on Exogenus Therapeutics: https://www.youtube.com/watch?v=6pyTMGNhPJc Event organizers, EBD Group and Johnson & Johnson Innovation, recognized how...

Exogenus was one of the 20 biotech startups selected to participate at Bio Europe 2017 Startup Slam taking place on November 7th in Berlin. Participants will have the chance to present in front of a jury of investors, dealmakers and biotech KOL's. Check out...

Exogenus was distinguished as one of the most innovative Life Sciences & Medtech projects in Europe at Merck Venture Lounge, 2017! The Venture Lounge is an initiative of EASME through SME Instrument Phase 3...

Joana Correia, Executive Director and Chief Scientific Officer presented last week at Cord Blood World Europe. Under the theme: "Umbilical cord blood supply for the development of Exo-Wound, an exosome-based product for chronic wounds" Joana talked about the...

Exogenus Therapeutics was one of the three finalist projects of the EWMA Alira Health 2nd Wound Care Innovation Symposium that took place on May 4th, at the European Wound Management Association Conference in Amsterdam. Having the opportunity to present its innovative...

It was announced last week that Joana Simões Correia, the Executive Director of Exogenus Therapeutics (Exo-T) is one of the Young Transatlantic Innovation Leaders of 2017. The Young Transatlantic Innovative Leaders Initiative Fellowship is the flagship program of the...

It was announced today that Exogenus Therapeutics (Exo-T) is the winner of the Everis Foundation Award 2016. The award, which every year distinguishes projects from Industry, Biotechnology & Health, and Digital Economy originating from countries where the Everis...

Exogenus Therapeutics (Exo-T) is one of the selected SMEs to receive support from the European Commission under the Horizon 2020's SME Instrument Phase 1. With the SME Instrument, the European Commission aims to support high growth, highly innovative European SMEs...

Exo-T are proud to have been chosen as one of the 6 finalists of the Everis Foundation Award 2016.  Selected among 600 projects of the areas of Industry, Biotechnology & Health and Digital, Exo-T is the only Portuguese representative left in the run-up to the...

Renato Cardoso is the new member of Exogenus Therapeutics' team. Renato is graduated in Chemistry, Master in Advanced Chemistry, and a PhD in Chemistry, with specialization in Biological Chemistry by the University of Coimbra.  

Watch Joana Correia's interview on Sic Noticias Edição da Manhã talking about Exo-T! http://goo.gl/tLVSB9

Exogenus Therapeutics features in i9 magazine's February edition. Check out this new paper and digital publication getting a grip on innovation pulse in Portugal! http://portal.i9magazine.pt/exogenus-therapeutics-regenera…/

A Exogenus Therapeutics, startup que conquistou recentemente o Prémio do Jovem Empreendedor com uma inovadora solução para o tratamento de feridas crónicas, acaba de fechar uma ronda de financiamento depois de captar 800 mil euros. O investimento foi assegurado pela...

The startup Exogenous Therapeutics, which was created with the support COHiTEC 2014, has raised a second round of funding worth 800 thousand euros, led by Caixa Capital. The funding will enable the company to advance the development of its innovative treatment for...

A startup que quer revolucionar a forma como se tratam feridas crónicas, provocadas por doenças como a diabetes, recebeu 800 mil euros numa ronda de investimento liderada pela Caixa Capital. A Exogenus Therapeutics recebeu 800 mil euros numa ronda de investimento...